Ian Reynolds manages Pew’s drug spending research initiative, which identifies policy options to help manage drug costs and ensure that patients have access to lifesaving treatments. Previously, he was an officer in Pew’s health group, where he led planning and development of new initiatives and coordinated the launch of projects.
Before joining Pew, Reynolds worked at Boston-based Community Catalyst to advance state and federal policies that improve conflict-of-interest standards in medicine and promote evidence-based practices. He also served as a Peace Corps volunteer in Turkmenistan, focusing on community health. Reynolds received a master of public health from Boston University and a bachelor’s degree from the University of Michigan.
Recent WorkView All
Of the 41 million Medicare Part D beneficiaries in 2016 (approximately 7.5 million of whom were also eligible for Medicaid), 12 million received a low-income subsidy (LIS, also known as Extra Help). The LIS helps beneficiaries with limited incomes to pay their Part D premiums and any cost-sharing on drugs, including deductibles and copayments. This assistance comes from subsidies the federal... Read More
Drug spending is a complex issue that involves a range of products, policies, and stakeholders across the health care system. Understanding the many factors that affect drug spending is critical to grasping how pharmaceuticals are priced and purchased. These definitions provide a frame of reference when examining the drug spending debate. Read More
Biological products, or biologics, are drugs made up of proteins or other materials derived from living cells through a complex manufacturing process. They are used to treat a wide range of health conditions, including cancer, rheumatoid arthritis, and multiple sclerosis, and are some of the most expensive drugs on the market, measured by both unit price and net contribution to spending. In 2015,... Read More